Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00418132 · ClinicalTrials.gov registry record · Phase 1
Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic Sclerosis
A Phase 1 study, sponsored by NYU Langone Health.
- Terminated
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00418132 is a Phase 1 study that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 30 participants.
The verdict
NCT00418132, a Phase 1 study, was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
Progressive systemic sclerosis (SSc) is an immune-based disease that causes abnormal connective tissue growth of the skin and internal organs. At this point, there are no effective therapies for treating SSc. Thalidomide is a medication that has been shown to stimulate an immune response that reduces the body's synthesis of collagen, the main component of connective tissue. This study will determine the effectiveness of thalidomide in treating adults with SSc.
Interventions
- DRUG Thalidomide
- DRUG Placebo thalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2000-08 |
| Est. Completion | 2007-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00418132
The ClinicalTrials.gov registry entry for NCT00418132 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Thalidomide is the first listed.
NCT00418132 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00418132 about?
NCT00418132 is a clinical study titled "Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic Sclerosis". Progressive systemic sclerosis (SSc) is an immune-based disease that causes abnormal connective tissue growth of the skin and internal organs. At this point, there are no effective therapies for treating SSc. Thalidomide is a medication that has been shown to stimulate an immune response that reduce...
What is the current status of trial NCT00418132?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2000-08. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00418132?
The interventions under investigation include: Thalidomide (DRUG), Placebo thalidomide (DRUG).
Who is sponsoring clinical trial NCT00418132?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.